MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Phase 2
Withdrawn
Conditions
Pancreatic Cancer
Interventions
Drug: Gemcitabine, placebo
First Posted Date
2012-05-15
Last Posted Date
2015-09-28
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registration Number
NCT01598584
Locations
🇨🇳

TianjinCIH, Tianjin, Tianjin, China

Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Phase 2
Conditions
T Cell Lymphoma
Interventions
First Posted Date
2011-09-07
Last Posted Date
2015-11-04
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT01430013
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

Not Applicable
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2011-07-13
Last Posted Date
2016-02-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
160
Registration Number
NCT01393080
Locations
🇨🇳

Tianjian Medical University Cancer Institue and Hospital, Tianjin, Tianjin, China

Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas

Not Applicable
Conditions
Carcinoma, Hepatocellular
Interventions
Procedure: Therapeutic Chemoembolization
First Posted Date
2011-07-13
Last Posted Date
2017-06-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
2840
Registration Number
NCT01393093
Locations
🇨🇳

Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)

Not Applicable
Conditions
Carcinoma, Hepatocellular
Interventions
Other: Therapeutic Chemoembolization
First Posted Date
2011-07-13
Last Posted Date
2015-12-18
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
2480
Registration Number
NCT01393197
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

GWAS Research of Lung Cancer in Tianjin

Conditions
Primary Carcinoma
Non-small Cell Lung Cancer
First Posted Date
2010-12-07
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
500
Registration Number
NCT01255059
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy

Phase 2
Conditions
Esophageal Cancer
Interventions
Procedure: side-to-side stapled esophagogastric anastomosis
Procedure: circular-stapled esophagogastric anastomosis
First Posted Date
2010-11-16
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT01242124
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China

Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)

Not Applicable
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2010-04-06
Last Posted Date
2013-01-29
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
25
Registration Number
NCT01099124
Locations
🇨🇳

Tianjin Medical University Cancer Institude and Hospital, Tianjin, China

Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction

Conditions
Malignant Biliary Obstruction
First Posted Date
2010-02-23
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
300
Registration Number
NCT01073514
Locations
🇨🇳

Tianjin Medical University Cancer Institude and Hospital, Tianjin, Tianjin, China

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase 2
Suspended
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2009-09-29
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
102
Registration Number
NCT00986284
Locations
🇨🇳

Tianjin Cancer Institute & Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath